ライフサイエンスコーパス: breathlessness

1 eased synchronicity with the amygdala during breathlessness.

2 the threat perception network for impending breathlessness.

3 upling were the main determinants of reduced breathlessness.

4 conditions experience distinct qualities of breathlessness.

5 d the relationship between changes in DH and breathlessness.

6 OPD) and an important contributing factor to breathlessness.

7 same as in men; more had shock, syncope, and breathlessness.

8 e respiratory muscles and relates closely to breathlessness.

9 atients with advanced disease and refractory breathlessness.

10 rface between sensation and cognition during breathlessness.

11 y stop cycling due to leg effort rather than breathlessness.

12 recurrent episodes of coughing, wheezing and breathlessness.

13 roduced a significant reduction in perceived breathlessness.

14 ment in elderly patients with effort-induced breathlessness.

15 current medication, history, and symptoms of breathlessness.

16 The primary outcome measure was breathlessness (0-10 numerical rating scale [NRS]), meas

17 ween the groups in end-exercise ventilation (breathlessness 25.7 L/min [16.3-32.0] vs leg fatigue 31.

18 the cardiology department with complaints of breathlessness, abdominal pain and hematuria for the las

19 Patients reported higher breathlessness after SBT compared with nurses and physic

20 to allergens causes intermittent attacks of breathlessness, airway hyper-reactivity, wheezing, and c

21 Breathlessness alone was a more commonly cited limiting

22 enrolled consecutive adults with refractory breathlessness and advanced disease from three large tea

23 the elements subserving the consciousness of breathlessness and air hunger is limited.

24 initial visit for patients who complained of breathlessness and at a second visit in a subgroup of pa

25 We also determined the association between breathlessness and demographic factors or respiratory ob

26 umns of the periaqueductal grey (PAG) during breathlessness and its conditioned anticipation.

27 pulmonary disease (COPD) is limited by both breathlessness and leg muscle fatigue.

28 ous or nebulised MgSO(4) improve symptoms of breathlessness and reduce the need for hospital admissio

29 Some symptoms such as breathlessness and shortness of breath seem not to be ev

30 rmly fatal, and characterised by progressive breathlessness and unremitting pain in the chest wall.

31 cade of changes that lead to severe fatigue, breathlessness and, ultimately, death.

32 function in patients with moderate or severe breathlessness, and no apparent relationship between bre

33 capnia, and exercise; breath-hold tolerance; breathlessness; and psychologic status.

34 -limbic correlations at rest, whereas during breathlessness anticipation, reduced functional synchron

35 oms, such as palpitations, chest discomfort, breathlessness, anxiety, and syncope, which significantl

36 There was a significant reduction in breathlessness as measured by Borg score (4.5 +/- 0.7 to

37 patients with diseases other than cancer and breathlessness as well as those with cancer.

38 uscles during inspiration (in-phase) reduces breathlessness associated with hypercapnia and resistive

39 separate stimuli to produce mild to moderate breathlessness (BR): Protocol 1, steady-state hypercapni

40 urther the effect of chest wall vibration on breathlessness ("breathing discomfort") in patients, we

41 e symptoms were wheeze, waking at night with breathlessness, breathlessness following exercise, and w

42 measured pulmonary function tests, exercise breathlessness by Borg score, and exercise flow volume a

43 Mean evening breathlessness changed by -0.3 points (-0.7 to 0.1) in t

44 From baseline to day 6, mean morning breathlessness changed by -0.9 points (95% CI -1.3 to -0

45 hat leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.

46 his study were: to examine the decriptors of breathlessness chosen by a large sample of patients with

47 tly decrease rates of hospital admission and breathlessness compared with placebo: intravenous MgSO(4

48 Change in VAS breathlessness did not differ between active treatments

49 of the nurses and physicians underestimated breathlessness (difference score, </=-2) compared with t

50 ese results suggest that patients limited by breathlessness due to ventilatory constraints can be ide

51 ssness, and no apparent relationship between breathlessness during the SBT and extubation outcome.

52 Comparisons of breathlessness, exercise volumes, and pressures were mad

53 in respect to wheeze (F = 5.6, p < 0.01) and breathlessness (F = 6.05, p < 0.01).

54 re donation-related symptoms (eg, tiredness, breathlessness, feeling faint, dizziness, and restless l

55 wheeze, waking at night with breathlessness, breathlessness following exercise, and waking with cough

56 ected statements that described qualities of breathlessness from a 15-item questionnaire and complete

57 selected phrases that described qualities of breathlessness from a 15-item questionnaire.

58 rg scale, and the qualitative descriptors of breathlessness from a 19-item questionnaire were assesse

59 A lesser peak breathlessness in DLT recipients approached statistical

60 brain blood flow during acute CO(2)-induced breathlessness in humans.

61 Symptoms of breathlessness in patients with heart failure with prese

62 ants reporting symptoms of wheeze, cough, or breathlessness in the previous 12 months and who were no

63 air delivered by nasal cannula for relief of breathlessness in this population of patients.

64 teral PAG (lPAG), where activity scaled with breathlessness intensity ratings, revealing a potential

65 Breathlessness is a common and distressing symptom, whic

66 Breathlessness is a prevalent and distressing symptom in

67 Patients' recall of their sensations of breathlessness is reliable and comparable to dyspnea wit

68 The sensation of breathlessness is the most threatening symptom of respir

69 ther a patient's recall of the experience of breathlessness is the same as that provoked by physical

70 tween groups of patients stopping because of breathlessness, leg fatigue, or both were assessed with

71 es from 2 instruments for self-assessment of breathlessness, Mahler's baseline dyspnea index (BDI) an

72 Our primary outcome was patient-reported breathlessness mastery, a quality of life domain in the

73 The breathlessness support service improved breathlessness mastery.

74 ng a questionnaire containing descriptors of breathlessness may help to establish a specific diagnosi

75 ients admitted to hospital within 7 days and breathlessness measured on a 100 mm visual analogue scal

76 ere able to differentiate patients with more breathlessness (measured by BDI and VAS for breathing) a

77 less than 50% predicted, and incapacitating breathlessness (Medical Research Council dyspnoea scale

78 in walking distance <450 m), and substantial breathlessness (MRC dyspnoea score >/=3).

79 her in patients stopping exercise because of breathlessness (n=12, median EMGdi%max 75.7% [IQR 69.5-7

80 o patients (62%) reported moderate or severe breathlessness (Numerical Rating Scales >/= 4).

81 ) for hospital admission and a change in VAS breathlessness of -2.6 mm (-7.0 to 1.8; p=0.253) compare

82 ) for hospital admission and a change in VAS breathlessness of 2.6 mm (-1.6 to 6.8; p=0.231) compared

83 c wheeze and slightly more nasal catarrh and breathlessness on exertion than nonsmokers.

84 t patients reported no change in symptoms of breathlessness or fatigue during the titration phase.

85 .74, p = 0.006) and having left a job due to breathlessness (OR = 2.72, 95% CI = 1.07-6.92, p = 0.036

86 ' 11-point Numerical Rating Scales scores of breathlessness, perception of feeling secure, and improv

87 sit 2 between descriptors for recall and for breathlessness provoked by walking was 68% (r = 0.69; p

88 s confirmed by a correlational analysis with breathlessness ratings.

89 intained during exercise, and the associated breathlessness reflects the hyperventilation.

90 The median intensity of breathlessness reported by patients was five compared wi

91 ntial confounders: cancer versus non-cancer, breathlessness severity, presence of an informal caregiv

92 d by troublesome symptoms such as refractory breathlessness; short-term palliative care; and, in sett

93 nting patients were randomly assigned (53 to breathlessness support service and 52 to usual care).

94 Mastery in the breathlessness support service group improved compared w

95 randomisation to 6 months was better in the breathlessness support service group than in the control

96 The breathlessness support service improved breathlessness m

97 allocated (1:1) patients to receive either a breathlessness support service or usual care.

98 The breathlessness support service was a short-term, single

99 ld be higher in patients stopping because of breathlessness than in those limited by leg fatigue.

100 le function may contribute to the feeling of breathlessness that has been well described in this pati

101 se patients with more severe and less severe breathlessness, the primary symptom of active alveolitis

102 Exertional breathlessness, the principal symptom of HF, has many ca

103 centres, both at rest and in the context of breathlessness threat.

104 a hallway to provoke a moderate intensity of breathlessness (to compare recall with direct experience

105 The duration of breathlessness was also reduced by NIV (p=0.025).

106 Breathlessness was assessed in 296 (89%) patients alloca

107 Subjective breathlessness was manipulated while end-tidal CO(2-) wa

108 Perceived breathlessness was measured with the Borg Scale of Respi

109 Underestimation of breathlessness was not associated with professional comp

110 years with self-reported current wheeze and breathlessness were identified from a random population

111 ventilation, peak heart rate, and perceived breathlessness were lower in KE than cycle exercise (p <

112 guidelines, the asthma symptoms are episodic breathlessness, wheeze, cough, tightness of the chest, a

113 G is involved with sensorimotor responses to breathlessness, while the vlPAG operates within the thre

114 shed disease, shorter walk distance, greater breathlessness, worse quality of life, and increased exa